Splash Beverage Group ($SBEV) has entered a licensing agreement with Argent BioPharma to acquire exclusive global rights to CannEpil®, a proprietary cannabinoid-based therapeutic developed for drug-resistant epilepsy (DRE). The asset arrives with established patient access in Europe and documented engagement with the U.S. Food and Drug Administration. The deal moves Splash Beverage beyond its beverage portfolio and into pharmaceutical therapeutics.
What CannEpil® Is
CannEpil® is a cannabinoid-based therapy formulated specifically for epilepsy, with its primary target indication being DRE — a form of the condition that does not respond to standard anti-seizure medications. The therapy is proprietary to Argent BioPharma. No composition details, active ingredient ratios, or manufacturing disclosures were included in the announcement.
European Access and FDA Engagement
CannEpil® has already reached patients in Europe, giving it a commercial and regulatory track record outside the United States. Splash Beverage cited existing FDA engagement as part of the asset's profile, positioning the therapy as having a defined pathway toward U.S. development. The source did not specify the stage of FDA engagement, the nature of any prior submissions, or a timeline for a U.S. filing.
Strategic Pivot for $SBEV
Splash Beverage Group is known primarily as a beverage company. The CannEpil® transaction represents a direct move into the therapeutic cannabinoid space, attaching the company to a condition — drug-resistant epilepsy — where approved cannabinoid treatments have previously drawn significant clinical and investor attention. The terms of the Argent BioPharma licensing agreement, including any upfront payments, milestones, or royalty structures, were not disclosed in the announcement.
What the Market Is Pricing
The source provides no financial figures: no deal value, no revenue projections, no development budget. Investors repricing $SBEV on this headline are doing so on strategic optionality alone — an exclusive global license, a European-validated asset, and a stated FDA engagement, with all economic terms undisclosed.